SCHEDULE: Armistice Capital Discloses 9.99% Stake in Evogene Ltd.

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 9.99% of Evogene Ltd.'s ordinary shares as of March 31, 2026.

Summary

• Armistice Capital, LLC and Steven Boyd collectively hold a 9.99% stake in Evogene Ltd.
• This ownership represents 1,104,906 ordinary shares.
• The filing is made under Schedule 13G, indicating passive investment.
• Armistice Capital, LLC acts as the investment manager for the Master Fund, which directly holds the shares.
• Steven Boyd, as the managing member of Armistice Capital, LLC, may be deemed to beneficially own these shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a standard disclosure of beneficial ownership and does not inherently signal positive or negative developments for the company's operations or stock performance.

Positives

• Significant ownership stake of 9.99% indicates substantial investor confidence.
• The filing is a Schedule 13G, suggesting a passive investment approach rather than an attempt to control the company.

Negatives

• The Master Fund disclaims beneficial ownership due to its investment management agreement with Armistice Capital, which could imply a complex ownership structure.

Risks

• Potential for increased scrutiny from regulators due to the significant ownership percentage.
• The passive nature of the investment could change, leading to potential future activism or changes in strategy.

Future Outlook

The filing does not contain forward-looking statements or guidance. It is a disclosure of beneficial ownership.

Management Comments

• Armistice Capital, LLC exercises voting and investment power over the securities of the Issuer held by the Master Fund.
• Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

Industry Context

StockSavvy.ai notes that significant ownership disclosures by investment firms like Armistice Capital are common in the biotechnology and agricultural technology sectors, where Evogene Ltd. operates. Such filings often precede or follow strategic assessments of the company's value and potential.

Stakeholder Impact

• Shareholders: The presence of a significant institutional investor may lead to increased focus on company performance and strategy.
• Management: May face increased engagement or pressure from Armistice Capital regarding corporate strategy and governance.

Next Steps

• Monitor future filings from Armistice Capital and Steven Boyd for any changes in ownership or strategic actions.
• Observe Evogene Ltd.'s corporate activities and performance for potential responses to significant shareholder presence.

Key Dates

Keywords

Evogene Ltd., Armistice Capital, Schedule 13G, Beneficial Ownership, Ordinary Shares, Investment Management, Steven Boyd, SEC Filing